At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 89 enrolled
Drug / intervention
HPG1860 +1 moredrug
Likely dose
HPG1860 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis
In Brief
A Phase 2 clinical trial evaluating HPG1860 and Placebo for NASH - Nonalcoholic Steatohepatitis. Completed, enrolled 89 participants across 1 site.
Detailed Summary
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNASH - Nonalcoholic Steatohepatitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
Enrollment StartNov 2021
First PostedApr 2022
Primary CompletionFeb 2023
Study CompletionMar 2023
TodayJul 2026
First PostedApr 20, 2022
Enrollment StartNov 22, 2021
Primary CompletionFeb 28, 2023
Study CompletionMar 28, 2023
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 4.2 years ago
Interventions
HPG1860drug
The dosage form for clinical research is a dry-filled capsule for oral administration manufactured as strengths of 3 mg, 5 mg, and 8 mg.
Placebodrug
Capsule